CompletedPHASE1, PHASE2NCT00373568
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Studying Leishmaniasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AB Foundation
- Principal Investigator
- Jaime Soto, MDCIBIC
- Intervention
- miltefosine: 2.5 mg/kg/day for 42 days(drug)
- Enrollment
- 25 target
- Eligibility
- 12-80 years · All sexes
- Timeline
- 2005 – 2007
Study locations (1)
- Palos Blancos, Palos Blancos, Bolivia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00373568 on ClinicalTrials.govOther trials for Leishmaniasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07487350Recurrent Visceral Leishmaniasis in HIV Co-InfectionInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGNANCT06983665Human Bioequivalence Study of Liposomal Amphotericin B for InjectionSichuan Huiyu Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT06798415Intralesional Injection of Metronidazole for the Management of Cutaneous LeishmaniasisHayder Adnan Fawzi
- RECRUITINGPHASE2NCT06797544Intralesional Injection of Levofloxacin for the Management of Cutaneous LeishmaniasisHayder Adnan Fawzi
- RECRUITINGPHASE2NCT06798402Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium StibogluconateAl-Mustafa University College
- RECRUITINGPHASE2NCT06550609Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral MiltefosineFundacion Nacional de Dermatologia
- RECRUITINGNCT06514560OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis PatientsInstitute of Tropical Medicine, Belgium
- RECRUITINGNANCT06307171Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential BiomarkersIRCCS Sacro Cuore Don Calabria di Negrar